Effectiveness of omalizumab in severe solar urticaria

Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature

“…A total of 16 reports, mostly case reports, a few small case series and one clinical trial were analysed in this review. After including the current case series (with 5 patients not previously reported in the literature), a total of 38 patients were identified, 26 patients (68.4%) responded favourable to omalizumab therapy (complete or partial responses) and 12 did not (31.6%).…”

“…Evidence about treatment with omalizumab for SU is still scarce. De Dios‐Velasquez et al summarized clinical responses to omalizumab in 13 cases affected by SU, reporting favourable responses in 69.2% (9/13) of cases and a partial response in 7.7% (1/13). A recent systematic review of the literature reported complete/partial response in 28 of 36 patients with SU …”

Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence

“…Several case reports describe full remission of solar urticaria. 39,41,42,[61][62][63][64][65][66][67] Initial doses in these cases ranged from 150 to 375 mg, although in some patients a higher dose of 450 mg was necessary to achieve complete symptom control. 62,68 Patients often relapsed 2 to 8 weeks after discontinuing treatment but then responded well to the next omalizumab injection.…”

Urticaria and Mastocytosis

“…Oral nonsedating antihistamines before sun exposure are effective in half of the patients(Lim et al 2018). Sun-protective measures are sufficient for mild forms of the disease, but if it fails, graduated exposure to UVA, omalizumab, plasmapheresis, or IVIG can be tried (deDios-Velázquez et al 2016). -Differential diagnosis: Polymorphic light eruption, erythropoietic protoporphyria, urticarial vasculitis, druginduced urticarial phototoxic reaction, and heat urticaria (Goetze and Elsner 2015).…”